IGC Pharma Gets New Patent From U.S. Patent And Trademark Office To Treat Stuttering, Tourette's Syndrome

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office (USPTO) has officially issued U.S. Patent No. 12,491,200, covering the Company's novel microdose-based cannabinoid treatment of stuttering (stammering) and Tourette's Syndrome.

The patent issuance follows the Notice of Allowance previously announced by the Company and now provides full intellectual property protection over a proprietary therapeutic approach that utilizes ultra-low doses of THC, alone or in combination with CBD or other agents, to modulate neural circuits involved in vocal disruptions, tics, and involuntary motor symptoms.